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Preclinical data are reported that support a human immunodeficiency virus (HIV) vaccine
strategy using recombinant canarypox–HIV vectors (ALVAC-HIV) to load human dendritic
cells (DCs) with HIV antigens. Clinical-grade DCs were infected with good manufacturing
practice–grade ALVAC-HIV vaccine constructs. ALVAC infection, HIV gene expression, and
DC viability and function were monitored by use of immunohistochemistry, flow cytometry,
blastogenesis assays, antigen-specific interferon (IFN)–g enzyme-linked immunospot assay,
and enzyme-linked immunosorbent assay protein detection. The vaccines infected both im-
mature and mature DCs, and intracellular HIV-1 Gag protein was detected within hours.
ALVAC-HIV induced DC maturation that was mediated by tumor necrosis factor–a and
induced DC apoptosis that was directly related to the length of vaccine exposure. Of impor-
tance, the infected DCs remained functional in T cell stimulation assays and induced HIV
antigen–specific CD8+ T cell production of IFN-g from cells of HIV-1–infected individuals.
These data support an ongoing HIV vaccine trial comparing conventional vaccine delivery
routes with ex vivo vaccine–loaded autologous DCs for immunogenicity in HIV-1–uninfected
volunteers.
Live viral vectors are being used increasingly as an effective
means of delivering vaccine immunogens. Recombinant ca-
narypox (ALVAC)–human immunodeficiency virus (HIV) type
1 vaccines have been administered with a good safety profile
to 12000 individuals, mainly among HIV-seronegative popu-
lations [1–7]. However, these vaccines are only modestly im-
munogenic, as defined by the elicitation of antigen-specific cy-
totoxic T cells, in about one-third of volunteers [8, 9]. The
generation of T cell immunity requires dendritic cells (DCs),
which convert antigens into immunogens [10]. This role gives
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rise to their description as “nature’s adjuvant” and is one reason
why new immunization and immunity-monitoring strategies of-
ten incorporate DCs [11, 12]. Recent advances in techniques
for the cytokine-induced differentiation of monocytes into DCs
[13, 14] have provided easier access to this important antigen-
presenting cell (APC), which had been a scarce cell type since
its discovery 30 years ago [15, 16]. Many clinical studies using
autologous DCs loaded with tumor antigens (immunotherapy)
are in progress [17–22]. These DCs induce antitumor immunity,
such as expanded cytotoxic T cell (CTL) activity within the
CD8 compartment [17]. In healthy human volunteers, a single
injection of mature monocyte-derived human DCs loaded with
multiple antigens (i.e., tetanus toxoid [TT], influenza matrix
peptide, and keyhole limpet hemocyanin) expands both CD4-
and CD8-specific immune responses [23]. The level of matu-
ration of the DCs may be of critical importance in the nature
of the immune response to DC-delivered antigen [24–26]. Re-
cent studies suggest that antigen-loaded mature DCs induce a
protective (T helper type 1) immune response, whereas antigen-
loaded immature DCs may “silence” the immune response via
expansion of interleukin (IL)–10–producing T cells.
With the hope of engineering better vaccines, new strategies
are being used in an attempt to target DCs. Since we planned
to test the in vivo immunogenicity of canarypox (CP) vectors
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infection of immature and mature human DCs with existing AL-
VAC-HIV vaccine candidates. We describe the reproducible gen-
eration of large numbers of clinical-grade human DCs and the
interactions of these cells with good manufacturing practice
(GMP)–grade ALVAC-HIV vaccines. The early expression of the
HIV p24 gag gene in transfected DCs was demonstrated by fluo-
rescence-activated cell sorter analysis and immunohistochemistry.
In addition, these studies show maturational effects of the vector
on DCs, with preservation of APC integrity and function in vitro.
Materials and Methods
Generation of clinical-grade human DCs. We adapted published
methods [27], using leukapheresis (RH Laboratories) as a source
of monocyte precursors to generate DCs. In brief, leukapheresis
blood products (ACD-A anticoagulation) were diluted 1:1 in PBS
or RPMI 1640 medium (BioWhittaker) and layered over Ficoll-
hypaque (Amersham Pharmacia Biotech) in a blood-to-ficoll ratio
of 2:1, to isolate peripheral blood mononuclear cells (PBMC). The
PBMC were washed repeatedly with PBS or RPMI 1640 at suc-
cessively lower g forces (250, 170, and 110 g) to remove platelets.
The PBMC then were frozen in X-VIVO 15 medium (BioWhitta-
ker) supplemented with 12.5% human serum albumin (Alpha Ther-
apeutics) and 10% dimethyl sulfoxide (Sigma). They were initially
frozen at 80C overnight and then transferred to the vapor phase
of liquid nitrogen the next morning. Before use, the cells were
rapidly thawed at 37C, and complete medium (cRPMI) was added
dropwise to the suspension. cRPMI is RPMI 1640 supplemented
with 1% autologous human plasma (heat inactivated), 2 mM L-
glutamine (BioWhittaker), and 20 mg/mL gentamicin (American
Pharmaceutical Partners). The cells were gently pelleted (100 g)
and resuspended in cRPMI at cells/mL, and 10 mL were65  10
plated onto Falcon cell culture dishes (BD Biosciences).
The thawed, cryopreserved cells were cultured for 1 h at 37C
in 5% CO2, and then the nonadherent cells were rinsed off. Fresh
cRPMI (10 mL) was added, and the adherent cells were placed
into culture overnight. The following day, the medium was replaced
with fresh cRPMI. Recombinant human IL-4 (800 U/mL; Cell
Genix) and granulocyte-macrophage colony-stimulating factor
(GM-CSF) (1000 U/mL; Immunex) were added on days 1 and 3.
On day 5, the cells were replated into 6-well plates at cells/55  10
well in 3 mL, and the cytokines (IL-4 and GM-CSF) were added
again. To generate mature DCs, 0.75 mL of autologous mono-
cyte–conditioned medium (MCM) was added to each well (20%
vol/vol) on day 6. MCM contains the cytokines needed to mature
DCs (i.e., IL-1b, IL-6, tumor necrosis factor [TNF]–a, and pros-
taglandin-E2) [27, 28]. On day 7, the cells were ready for baseline
phenotyping (flow cytometry) and loading with CP either as im-
mature (without MCM) or mature (with MCM) DCs.
The phenotype of the DCs was routinely monitored by 2-color
fluorescence-activated cell sorter analysis on a FACScan flow cyto-
meter (Becton Dickinson) using BDIS/PharMingen phycoerythrin
(PE)–conjugated monoclonal antibodies to IgG1, IgG2b, CD1a, CD3,
CD14, CD20, CD25, CD80, CD86, and HLA-DR. PE-conjugated
monoclonal antibodies to CD40 and CD83 were from Immunotech
Beckman Coulter.
MCM preparation. Frozen PBMC (and, in some experiments,
fresh PBMC) were used to generate MCM. Falcon cell culture dishes
used to generate MCM were pretreated with human intravenous
immunoglobulin (IVIG; gift from Bayer, North America) in PBS
(100 mg/mL) for 10 min at room temperature. The plates were washed
3 times with 10 mL of PBS to remove excess IVIG. Cells were thawed
and plated onto IVIG-coated plates at cells/mL in 10 mL,65  10
as described elsewhere [27]. The plates were incubated overnight, and
the cell-free MCM supernatant was collected, filtered (0.2 mL), and
frozen at 80C prior to use.
ALVAC HIV vaccine constructs. All ALVAC-HIV vaccines
were obtained from Aventis Pasteur. CP viruses are members of
the avipox genus of the Orthopoxvirus family of DNA viruses and
are highly restricted in terms of productive replication to avian
species. ALVAC-HIV (vCP205) is a preparation of recombinant
CP virus expressing the products of the HIV-1 env, gag, and pro
genes. These genes are inserted into the C3 locus and are regulated
by the vaccinia virus H6 and I3L promoters. vCP1433 is equivalent
to vCP205 with the addition of nef and pol CTL epitopes. vCP1452
is equivalent to vCP1433 under different promoters (E3L and K3L)
and vCP1521 is env/gag-clade E/pro (similar to vCP205).
Loading DCs with CP. Preliminary work was done using lab-
oratory-grade CP constructs that were suspended in serum-con-
taining media solutions, as described elsewhere [29]. When tran-
sitioning to using the GMP-grade lyophilized vaccines, there was
a rapid loss of cell viability after exposure to vaccines that were
resuspended as directed for routine injection (1 mL of sterile H20).
However, when the vaccines were resuspended in enough sterile
H20 (range, 1.6–1.9 mL) to achieve physiologic osmolality (280–300
milliOsmoles [mOsm]), the DCs remained viable. The vaccines
ranged in titer from 106.4 to 106.8 TCID50, as determined by plaque
assay. A single vial of vaccine (∼106.5 infectious virus particles) was
used to load 2– DCs, which resulted in an MOI of 2.5. The63  10
cells were exposed to the vaccine for 2 h (or less in some experi-
ments) at 37C in 5% CO2. The cells were washed and counted,
and viability was checked by use of trypan blue exclusion and, in
some cases, annexin-V and propidium iodide (PI).
Determination of infection rates and gene expression. After vac-
cine exposure, the cells were washed, resuspended in cRPMI at 106
cells/mL, and placed back into culture. At specified time points af-
ter vaccine exposure, the cells were washed, fixed, permeabilized
(PharMingen Fix and Perm Kit), and stained intracellularly for both
CP (polyclonal rabbit anti-CP virus serum at 1:10,000 dilution; Vi-
rogenetics) and HIV-1 p24 (murine monoclonal antibodies at 1:10
dilution; Dako) antigens. These primary antiviral antibodies were
detected by use of PE-conjugated secondary antibodies (goat anti-
rabbit or goat anti-mouse) at 1:200 dilutions (Southern Biotech-
nologies Associates). In some experiments, the cells were double la-
beled using anti-p24, as described above, and anti–CD83–fluorescein
isothiocyanate (FITC)–conjugated monoclonal antibodies.
Maturation (TNF) blocking studies. DCs were exposed to vac-
cine or medium, usually for 2 h, and then were washed with fresh
cRPMI to remove excess virus. The exposed cells were split into
2 aliquots and were either treated with IgG1 control antibody
(PharMingen) or neutralizing anti–TNF-a antibody (R&D Sys-
tems) at a concentration of 20 mg/mL, as described elsewhere [29].
The cells were collected within 24 h, and surface staining for mat-
uration markers was performed.
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ing kits (PharMingen) were used according to the manufacturer’s
guidelines to identify cells undergoing apoptotic and/or necrotic
cell death.
Immunohistochemistry. After vaccine exposure, ∼ DCs52  10
were spun onto glass slides, using a Cytospin (Shandon Lipshaw)
set at 50 g for 10 min. After being air-dried, the slides were fixed
in acetone and stored at 20C until staining commenced. The
slides were warmed to room temperature, rehydrated in PBS, and
permeabilized with 0.1% saponin (Sigma) for labeling of intracel-
lular antigens. All antibodies were diluted in the appropriate
“blocking” serum and incubated for 30 min with antibodies at room
temperature. Slides were washed for 10 min in PBS with gentle
stirring. Staining was done in parallel on unexposed cells (mock
infected), and appropriate isotype controls were used to assess
background for each experiment.
Lymphoproliferation assays. Allogeneic T cell proliferation as-
says were performed as follows. T cells were isolated from PBMC
by negative selection, using a T cell–negative isolation kit (Dynal
Biotech) containing antibodies to CD14, CD16, CD56, and HLA-
DR/DP, according to the manufacturer’s guidelines. In brief, the
cells were incubated with the antibody cocktail for 10 min at 4C
and then washed to remove excess antibody. Next, the magnetic
beads were added, and the cells were gently rotated at room tem-
perature for 15 min. The cell suspension was placed into a magnetic
field to remove unwanted cells (those other than T cells). To en-
hance purity, the T cells were placed into the magnetic field twice.
These T cells were plated into 96-well round-bottom plates (Costar)
in triplicate and cocultured at cells/well with various con-52  10
centrations of DCs. Alloreactions were incubated at 37C under
5% CO2 for 3–5 days, pulsed with 1 mCi/well [
3H]thymidine
(DuPont) for 18 h, and harvested onto filter mats for scintillation
counting in a 1450 Microbeta Trilux (EG&E Wallac).
Autologous T cell proliferation assays were done as follows. These
assays were performed in the same manner as the above alloreactions,
with the exception that autologous experiments used re-51  10
sponder cells and were incubated for 5–6 days. TT (3.2 limits of
flocculation) was added directly to the wells. After incubation, the
cells were pulsed with 1.6 mCi/well [3H]thymidine for 18 h, harvested,
and counted as described above. Supernatants (100 mL/well) were
collected immediately prior to the thymidine pulse and frozen
(80C) until analyzed for interferon (IFN)–g production.
Antigen-specific IFN-g production detection using ELISPOT as-
says. DCs were generated from frozen aliquots of PBMC from
HIV-seropositive individuals who had undergone leukapheresis as
part of a clinical trial (RV100). The cells were thawed and prepared
as described above for seronegative donors. In general, the ELISPOT
assays were performed by directly stimulating PBMC with the an-
tigens or by stimulating PBMC with antigen-loaded DCs. The PBMC
were added to the assay plates at cells/well. Ninety-six–well52  10
ELISPOT plates (Multiscreen-IP MAIP type plates; Millipore) were
prepared by precoating with mouse anti–human IFN-g antibody
(MAb 1-D1K; Mabtech) at 5 mg/mL in 50 mL of PBS overnight at
4C. Plates were washed 5 times with PBS and blocked with 100 mL
of complete medium (RPMI 1640 medium [BioWhittaker] and 10%
normal human serum [Sigma]) for 1 h at 37C.
For evaluation of CD8 T cell dependence, the PBMC were split
into 2 aliquots and treated with Dynabeads M-450 CD8 or M-450
sheep anti–mouse IgG (Dynal Biotech) for CD8 and sham deple-
tions, respectively. The immunomagnetic beads and cells that ad-
hered to the beads were removed with a magnet, and the resulting
cell populations were washed twice and resuspended in complete
medium. On the basis of the cell count in the sham depletion,
between and PBMC were added to each well of5 51  10 2  10
the precoated and blocked ELISPOT plate. vCP205- or vCP1452-
exposed DCs (or mock or ALVAC empty vector infected) were
washed once after infection and distributed in duplicate or tripli-
cate wells at a count of – cells/well (ratio of 20:1,4 40.5  10 1  10
PBMC:DCs). The negative control and ALVAC control wells were
all done in quadruplicate. As a positive control for functional in-
tegrity of the cells, either phytohemagglutinin-P or staphylococcal
enterotoxin–B was added to duplicate wells at a final concentration
of 5 mg/mL. For the direct vCP205 addition experiments, 52  10
PBMC were added to each well of the ELISPOT plates, and AL-
VAC was added directly to the wells at 5 pfu/cell. Plates were
incubated for 20–24 h at 37C (5% CO2) and were then washed
with PBS/0.05% Tween 20 buffer and incubated for 2 h with mouse
anti–human IFN-g antibody conjugated with biotin (7B6-1–biotin;
Mabtech). Development consisted of a 1-h incubation with an av-
idin–horseradish peroxidase complex (Vectastain ABC kit; Vector
Laboratories), followed by washing (PBS/0.05% Tween 20 buffer)
and incubation with peroxidase substrate AEC (Vector Labora-
tories) for 4 min.
ELISA-based cytokine detection assays. TNF-a was detected
as a secreted protein product in culture supernatants by use of a
specific commercial ELISA assay (R&D Systems). Assays were
performed according to manufacturer’s guidelines. The lower de-
tection limit for TNF-a was 16 pg/mL.
Statistical analysis. Microsoft Excel 98 was used for statistical
analysis of data (paired Student’s t test).
Results
CP infection and HIV Gag protein expression in GMP vac-
cine–exposed DCs. DCs were generated from frozen aliquots
of PBMC from donors who underwent leukapheresis, and, if
indicated, matured with MCM, as described elsewhere [27]. On
average, we obtained a yield ( ) of5.3%  0.3% n p 42  SEM
fully mature DCs from each culture. Figure 1A shows the typ-
ical phenotype of immature and mature (after MCM exposure)
DCs. In particular, mature DCs express high levels of CD83
and CD86. There is minimal contamination from T and B cells.
Figure 1B shows the morphology of mature DCs in culture on
day 7.
Immature and mature DCs were exposed to ALVAC-HIV
and evaluated for expression of CP and HIV antigens. For
intramuscular use (the usual delivery route), the lyophilized
vaccine is resuspended in 1 mL of H20. However, this results
in supraphysiologic osmolality, which is not tolerated by DCs
in culture. Thus, prior to exposure of DCs to ALVAC-HIV, we
adjusted the volume of the vaccine to 1.6–1.9 mL to provide
physiologic osmolality (i.e., 280–300 mOsm). After vaccine ex-
posure, the DCs were analyzed at both early (4–6 h) and late
(18–24 h) time points to determine infection rates (CP) and
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Figure 1. Dendritic cell (DC) phenotype, DC morphology in culture, and canarypox (CP) and p24 gag expression in DCs. A, DCs prepared
by adherence and matured (heavy black line) using monocyte-conditioned media (MCM) contain infrequent contaminating T (CD3) or B (CD20)
cells and express minimal CD14 and high levels of HLA-DR, CD83, and CD86. Immature DCs (no MCM; fine black line) demonstrate lower
levels of HLA-DR, CD83, and CD86. Filled gray histogram represents the relevant isotype controls. B, Phase contrast microscopy demonstrating
nonadherent mature DCs in a 6-well culture dish on day 7 (scale bar, 20 mm). C, Immature and MCM-matured DCs were exposed to vaccine
for 2 h, permeabilized, and then labeled with anti-CP and p24 antibodies for fluorescence-activated cell sorter analysis, as described in Materials
and Methods. The histograms represent mean CP and p24 expression (SEM) 4 h after vaccine exposure ( donors). D, Immunohistochemistryn p 3
staining for intracellular p24 (blue) and HLA-DR (brown) at the 4-h time point shows that all cells are HLA-DR and that ∼15% are expressing
intracytosolic p24 (scale bar, 20 mm). E, Distribution of expressed intracellular p24 protein (within immature or mature DCs populations) depends
on initial maturity levels of the exposed DCs. There is equal distribution of p24 in CD83 and CD83 fractions when the majority of starting
DCs are immature (left). If the DCs are mature when exposed (right), most p24 protein colocalizes within the CD83 DCs. A representative








niversity Library user on 11 August 2020
1246 Marovich et al. JID 2002;186 (1 November)
Figure 2. Maturation induced by exposure to canarypox vaccine. A, Immature dendritic cells (arrow) without vaccine exposure and subsequent
phenotype observed 24 h after vaccine exposure demonstrate profound maturation with increased expression of all markers in a representative
donor ( ). B, Use of a neutralizing anti–tumor necrosis factor (TNF)–a antibody can partially block vaccine-induced maturation, as shownn p 5
by the inhibition of CD83, CD86, and CD40 up-regulation in this representative blocking experiment ( ).n p 3
antibody preparation and a monoclonal anti-Gag antibody.
The percentage of cells positive for CP or Gag antigens was
determined by flow cytometry, using relevant isotype controls
and mock-infection conditions to set gates for background
staining. Figure 1C shows that exposure of immature or mature
DCs to ALVAC-HIV results in expression of CP antigens in
∼50% of DCs. About one-quarter of the CP-positive DCs also
expressed HIV-1 Gag protein. Figure 1D shows the immuno-
histochemical staining of intracellular p24 protein (blue) dis-
tributed throughout the cytoplasm of ∼15% of the DCs at 4 h
after ALVAC-HIV infection. The brown stain labels surface
HLA-DR and identifies these cells as major histocompatibiltiy
complex (MHC) class II–bearing APCs. Figure 1E shows flow
cytometric dot plots of DCs stained for surface CD83 and for
intracellular p24 Gag (note the 18-h time point in the figure
legend). When infecting initially immature DCs, note that the
p24 protein was evenly distributed between immature and re-
sultant mature DC populations (lower left); however, when
starting with a more mature population (right panel), most p24
protein was colocalized to mature CD83 DCs (lower right).
Vaccine-induced maturation of clinical-grade cultured human
DCs. As we reported elsewhere [28], using a laboratory-grade
vector, CP infection of DCs results in a TNF-a–mediated ma-
turational effect on immature DCs. Using the GMP-grade AL-
VAC-HIV vaccine, we also noted a profound maturational ef-
fect (figure 2A), which was mediated in part by TNF-a (figure
2B). Nonrecombinant ALVAC (empty vector) also induced
maturation of DCs (data not shown). In most donors, full
maturation of DCs was observed within 24 h of CP infection.
The arrows in figure 2A represent the immature DC phenotype
under mock-infection conditions (medium only). This repre-
sents the starting population phenotype. After vaccine exposure
and overnight incubation, most of the cells matured, as evi-
denced by the increased expression of all surface markers shown
(figure 2B). However, only the expression of CD83, CD86, and
CD40, as measured by mean fluorescence intensity, were con-
sistently and significantly inhibited (150%) in the presence of
the anti-TNF antibody. In the blocking experiments, we used
an anti–TNF-a antibody that blocked both soluble and
membrane-bound TNF-a or an IgG control antibody in both
mock- and vaccine-infected DCs. The vaccine-induced matu-
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Figure 3. Similar expression of canarypox (CP) and p24 in mature dendritic cells (DCs), using various good manufacturing practices–grade
lyophilized vaccine constructs (vCP205, vCP1433, vCP1452, and vCP1521). A, Histograms represent the mean CP and p24 expression (SEM)
4 h after vaccine exposure ( donors). B, Vaccine titration curve in a representative donor (1 of 3 tested), using CP p24 antibody detectionn p 3
in fluorescence-activated cell sorter analysis comparing 2 different lots of vCP205 demonstrating an optimal MOI of 2–5.
increase in CD83 expression in both DC populations after
vCP205 exposure (figure 1E, left panel, top to bottom, CD83
increased from 22% to 63%; right panel, top to bottom, CD83
increased from 69% to 88%). Of interest, we observed that
immature DCs produced ∼10-fold more TNF-a than did ma-
ture DCs ( vs. pg/mL; donors;571.4  128 61.0  30.5 n p 5
) after vaccine exposure. Since the mature DCs wereP ! .009
readily infected with CP, we focused on loading mature cells.
Similar infection rates and Gag expression using various vac-
cine constructs. Several CP HIV-1 vaccine constructs have
been developed for clinical studies. Most human clinical trial
experience is with an earlier construct, vCP205. Subsequent
constructs included additional HIV-1 genes and different pro-
moter control. We compared the rates of expression of CP
antigens and HIV Gag protein 4–6 h after exposure to 4 dif-
ferent ALVAC-HIV vaccine constructs and 2 different lots of
vCP205. As shown in figure 3A, all ALVAC-HIV constructs
displayed similar levels of CP and p24 Gag expression in DCs.
Of note, CP and Gag expression was measured at 4–6 h because
this time point was optimal for vCP205 (maximal p24 Gag
expression). In addition, we compared the 2 different lots
vCP205 in titration assays using mature DCs as the target cells.
The reported TCID50 per vial of vaccine (range, 10
6.4–106.8) was
used to calculate the MOI. As can be seen in figure 3B, there
was comparable CP infection and gag expression between the
two vaccine lots of vCP205, with an optimal MOI of 2–5.
CP induction of apoptosis in vaccine-exposed DCs. An ap-
pealing feature of CP as a viral vector is that the virus is non-
pathogenic for humans. However, several reports document
that CP induces apoptosis in infected DCs [29, 30], with im-
mature DCs being more susceptible than mature DCs. It has
also been reported that CP-infected apoptotic DCs can be taken
up by uninfected DCs and cross-presented for T cell stimulation
in vitro [30]. Indeed, we found more cell death in immature
DCs than in mature DCs after vaccine exposure. At 24 h after
infection, the mean (SEM) viability of immature and mature
DCs was 64% (6.6%) and 80% (5.1%), respectively (P !
). Subsequent experiments focused on mature DCs to op-.018
timize susceptibility to CP infection while controlling for the
amount of cell death. Using a sensitive assay involving a com-
bination of annexin-V and PI staining, we detected more non-
viable DCs (24 h after a 2-h vaccine exposure) than by using
trypan blue exclusion alone (figure 4A). As expected, the trypan
blue and PI measurements were closely correlated ( ),r p 0.8
because annexin-V–labeled cells can still exclude trypan blue
and PI. We also noted that after vaccine exposure, DC viability
was influenced by the type of culture medium (RPMI 1640,
PBS, or saline) used to maintain the cells after loading (figure
4B). The DC viability decreased substantially over time when
maintained in PBS or saline, compared with RPMI 1640 me-
dium. The DCs were much less affected by storage temperature
(figure 4C), although 37C seemed to be optimal.
Finally, we observed that the amount of induced apoptosis
was directly related to the length of time the cells were exposed
to the vaccine (figure 4D). Thus, with regard to ex vivo loading
and delivery of DCs, the 2-h vaccine exposure would allow
sufficient time for infection of DCs, with some downstream
apoptosis, and for a largely viable product to be delivered.
Vaccine-exposed DCs retain APC function. To ensure that
the DCs would remain functional despite being infected with a
live viral vector, we used stimulation of the mixed lymphocyte
reaction to assess DC function. Negatively selected responder T
cells were cultured with titrated amounts of allogeneic DCs (ex-
posed to vCP205 or saline). After 3–5 days of culture, the
vCP205-DCs retained full and strong stimulatory reactivity, as
shown in figure 5A. To test presentation of protein antigen by
ALVAC-HIV–infected DCs, we studied autologous tetanus an-
tigen-specific lymphoproliferation. After DC exposure to vCP205
vaccine or saline, DCs were added in graded doses to a fixed
number of autologous responder T cells and then incubated with
TT. After 5–6 days of culture, the cells were pulsed with [3H]thym-
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Figure 4. Canarypox-induced apoptosis in exposed mature dendritic cells (DCs). A, DCs were exposed to vCP205 for 2 h, and cell viability
was assessed 24 h later by use of trypan blue exclusion (TBE) and an annexin-V propidium iodide (PI) assay. Annexin-V and PI are shown in
darker stacked histograms, and the trypan blue–positive cells are shown in gray for individual donors ( ). B, DCs generated from frozenn p 4
peripheral blood mononuclear cells from 2 different donors (thawed after 6–9 months of cryopreservation) were exposed to vCP205. Viability
was monitored using TBE in cells that were resuspended in RPMI 1640 medium, PBS, or saline. Dotted line, 70% viability cutoff (required for
release). Unexposed DCs (mock) remained more viable over time, and loaded DCs preferred medium to other solutions. Two of 3 representative
experiments are shown. C, Temperature dependence of viability (TBE) of vaccine-loaded DCs from a representative donor (1/3) compared at
37C vs. 4C. D, Apoptosis measured 24 h after vaccine exposure (30 vs. 120 min) in a representative donor. Unexposed DCs kept in medium
show 12%–13% annexin-V positivity. Similar levels of apoptosis were observed after brief exposure to the vaccine (30 min), but apoptosis nearly
doubled with longer vaccine exposure times (120 min).
shows that vCP205-exposed DCs were more efficient than unex-
posed DCs in presentation of TT to autologous T cells. Finally,
we tested the ability of vCP205-exposed DCs to present HIV
antigens to sensitized T cells. We used the ELISPOT assay in an
autologous system to detect antigen-specific CD8 T cell pro-
duction of IFN-g. Frozen PBMC were used to generate autol-
ogous DCs that were loaded with either the empty vector (AL-
VAC) or ALVAC-HIV (vCP205 or vCP1452). PBMC were added
to the ELISPOT plate and either stimulated directly with medium
(ALVAC, vCP205, or vCP1452) and phytohemagglutinin-A or
stimulated via antigen-loaded DCs. vCP205-loaded DCs clearly
induced HIV antigen–specific IFN-g, which is largely derived
from CD8, as demonstrated using CD4 and CD8 cell–depletion
techniques (figure 5C).
Discussion
Live recombinant CP viral vectors represent a safe method
for delivering vaccine antigens; however, immunogenicity may
not be optimal under standard immunization conditions of in-
tramuscular delivery. One approach to improve vaccine im-
munogenicity is to target the vaccine antigens directly to DCs
in vivo. Here, we have studied the interaction of ALVAC-HIV
constructs with monocyte-derived human DCs. We report pre-
clinical findings, using an ex vivo vaccine–loading method to
ensure that the DCs were infected with the vector and could
express and present HIV-specific antigens.
We used GMP-grade lyophilized vaccine (vCP205 and other
ALVAC HIV constructs) to infect clinical-grade human DCs.
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Figure 5. Retention of dendritic cell (DC) function after canarypox (CP) exposure. A, vCP205-exposed immature DCs induced higher levels
of DNA synthesis, compared with unexposed immature DCs, in a standard alloreaction. B, In an antigen-specific autologous system, CP-exposed
monocyte-conditioned medium (Med)–matured DCs induced a stronger recall proliferative response to tetanus, compared with unexposed mature
DCs. C, In human immunodeficiency virus (HIV)–seropositive persons, using an interferon (IFN)–g ELISPOT assay system, vCP205 (205)–loaded
DCs but not recombinant CP (ALVAC)–infected DCs (ALV; empty vector) presented relevant HIV antigens, driving a CD8-specific response.
Results are from a representative donor, with a minimum of 3 experiments performed. PBMC, peripheral blood mononuclear cells.
the CP vaccine; ∼50%–60% of DCs expressed CP antigens and
about one-third of these DCs expressed HIV Gag protein. In
an effort to standardize DC immunization in planned vacci-
nation trials, we used leukopheresis-derived mononuclear cells
as the DC precursor source and MCM as the maturational
signal [27]. Although there was some variability in maturation
induced by MCM, we consistently found that 150% of the DCs
expressed CD83 after exposure to MCM. Even with MCM-
matured DCs, we observed further maturation of the cell pop-
ulation after exposure to vaccine. We infected immature and
mature DCs and compared subsequent p24 expression patterns
in both cell types. There was comparable CP infection and p24
Gag expression in both the initially immature and mature DC
populations. However, the maturity of p24 Gag–expressing cells
was different in the 2 cell types. Most p24 Gag–expressing cells
were CD83 if the starting population was mature, but p24
was evenly distributed between CD83 and CD83 DCs if the
starting population was immature. Although CD83 function is
incompletely understood, it is commonly used as a marker of
DC maturation, and its expression recently has been linked
with the ability to induce protective (T helper type 1) immune
responses to test antigens in human clinical trials [31]. Since it
is important to have a population of mature DCs to elicit op-
timal immune responses, these data suggested that our planned
clinical study should be done by loading mature DCs with CP.
This approach minimizes the chance of injecting Gag-express-
ing immature DCs.
Exposure of immature DCs to ALVAC constructs resulted
in a profound maturational effect that was partly mediated by
TNF-a. This maturational effect with laboratory-grade CP vec-
tors was reported elsewhere [29]. In contrast, vaccinia virus
actually inhibits DC maturation [32] and function [33]. Similar
inhibitory effects are seen with herpes simplex vectors [34, 35],
whereas other viral vectors (e.g., adenovirus) do not influence
maturation [36]. Regarding TNF-a production, the expression
of this cytokine by skin DCs may be a beneficial feature of a
vector, since TNF-a has been directly associated with the mi-
gration of Langerhans’ cells out of the epidermis [37, 38]. In
addition, the maturation state and the migratory ability of DCs
are thought to be closely linked [39], although there are likely
other factors influencing DC trafficking (e.g., chemokines)
[40–42]. We found that immature DCs produced ∼10-fold more
TNF-a after vaccine exposure, compared with mature DCs. In
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as CD25, CD40, CD80, CD86, and MHC classes I and II. The
increased expression of some of these molecules (CD40, CD83,
and CD86) could be substantially blocked by use of an anti–
TNF-a blocking antibody, suggesting a role for TNF-mediated
maturation. The increased expression of both types of MHC
molecules after exposure to a virus is interesting and encour-
aging with regard to retention of APC function and stimulation
of potential CD4 and CD8 responses.
A single injection of monocyte-derived mature DCs pulsed
with keyhole limpet hemocyanin, influenza matrix peptide, and
TT has been shown to expand specific CD4 and CD8 immune
responses in healthy volunteers [23]. Recent reports indicate that
the delivery of antigen-loaded immature DCs into humans can
have an immunosuppressive effect via the induction of antigen-
specific IL-10–producing T cells [24, 26, 31]. With data emerging
regarding the link between DC maturation and improved mi-
gration and the potential immunosuppressive role of the im-
mature DCs and with the ability to infect either type of DC, we
chose to concentrate our efforts on loading the mature DCs.
The distribution of Gag protein was mainly intracytosolic,
as shown in figure 1D. The expression of Gag was detected
very early and decreased over time, with a maximal expression
at ∼4–6 h after vaccine exposure. However, the ability to detect
de novo synthesized protein (using a monoclonal antibody)
within a DC is balanced by the fact that these cells are addi-
tionally processing and loading the antigen into MHC mole-
cules. Along these same lines, the maturation level of the DCs
may influence the rate and efficiency at which these protein
products are processed (authors’ unpublished results). Despite
viral infection, protein production, processing and loading of
MHC molecules, cytokine secretion, and cellular maturation,
we found that the cell populations remained viable and were
functional in assays of T cell stimulation.
Safety concerns currently require that all final products un-
dergo stringent release testing prior to injection into humans.
These tests, gel clot assays for the detection of endotoxin in
particular, require at least 90 min to perform. Other logistics
(e.g., cell phenotyping, viability testing, or volunteer arrival) may
require that the cells remain in an injectable solution, as the tested
and unaltered final product, for some time (several hours) prior
to their injection. Maintaining vaccine loaded DC integrity in
this injectable solution is an important goal of DC-based vac-
cinations. We found that keeping the DCs at 37C, compared
with 4C, was best but that the cells clearly preferred medium
or PBS to saline; however, no such buffered solutions exist that
are suitable for injection. The best approach ultimately would
be to inject antigen-loaded mature DCs as efficiently and safely
as possible, allowing in vivo priming to commence.
We and others have reported previously that CP induces ap-
optosis in DCs [29, 30]. In these experiments, we found that
higher MOIs (MOI, 10) and immature DCs resulted in a greater
amount of DC apoptosis. Others have recently shown cross pre-
sentation of tumor antigen via the uptake of apoptotic DCs
(induced by loading immature DCs with ALVAC encoding the
melanoma-associated antigen, Melan-A/MART-1) in a mela-
noma model [30]. This latter observation raises the possibility
that the apoptotic CP-loaded DCs could be cross-presented by
DCs in vivo. We balanced the length of exposure to vaccine
required for optimal loading and tolerable levels of apoptosis
induced by vaccine exposure to allow a largely viable cell product.
Of interest, we did note a consistent increase in the ability
of the CP-exposed DCs to stimulate T cells in both the mixed
lymphocyte response (alloreactivity) and antigen-specific pro-
liferation assays. This may be due to the associated maturation
and activation effect from the CP itself. This suggests the po-
tential for enhanced processing of endogenous proteins when
a DC is exposed to appropriate maturational signals [43, 44],
as has been shown in a murine model for exogenous MHC
class II processing [45]. Finally, we found that the CP-loaded
mature DCs could process and present relevant HIV antigens
to autologous, IFN-g–producing CD8 T cells (figure 5C). This
has been demonstrated by others [46] and may support a role
for DC immunotherapy in HIV-seropositive individuals, if the
nature of the resultant CTL response could be improved. In-
deed, the ability of DC vaccination to broaden the CTL re-
sponse by expanding the T cell repertoire of a given epitope
recently has been demonstrated using a transgenic mouse model
and DCs loaded with a single peptide [47].
In summary, we have shown that GMP-grade lyophilized
ALVAC-HIV vaccine constructs can be used to load clinical-
grade human DCs with HIV genes. ALVAC-HIV vaccines in-
duced TNF-a–mediated maturation of DCs. The vaccine-
loaded DCs retained functional activity in allogeneic and
autologous T cell assays. Vectored HIV genes were expressed
early within the DCs. Of importance, expressed HIV proteins
were processed and presented to sensitized CD8 T cells, re-
sulting in HIV antigen–specific IFN-g production in vitro.
These results laid the foundation for an ongoing, proof-of-
concept phase 1 trial, to optimize antigen presentation using
ex vivo targeting of DCs in HIV-seronegative volunteers.
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